Shares of Moderna (MRNA.US) are trading higher as the company relayed that its vaccine mRNA-1345 against RSV (respiratory syncytial virus) effectively prevents the development of the disease in older adults (phase III research vaccine development results).
- The company expects to file for approval with the Food and Drug Administration (FDA) in the first half of this year.
- Moderna shares are up nearly 8% before the Wall Street session and are trading around 205 USD.
Moderna's shares have been in an uptrend since the company broke the news in the fall of 2022 that it was collaborating with Merck (MRK.US) on a promising anti-cancer therapy. The price on the H1 interval has climbed above the 100 (black line) and 200-session (red line) moving averages, and an opening above $200 could open a path for bulls toward the mid-December highs, when the stock was trading at $217 per share. Moderna will show Q4 2022 results on February 2.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app
Moderna shares (MRNA.US), H1 interval. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
